Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:3119 |
Name | gastrointestinal system cancer |
Definition | An organ system cancer located_in gastrointestinal tract that is manifested in organs of the gastrointestinal system. |
Source | DiseaseOntology.org |
Alt Ids | DOID:4945 DOID:8377 |
Path | disease disease of cellular proliferation cancer organ system cancer gastrointestinal system cancer |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
PIK3CA E542K | Capivasertib | gastrointestinal system cancer | sensitive | detail... |
PIK3CA E545K | Capivasertib | gastrointestinal system cancer | sensitive | detail... |
BRAF D594G | Trametinib | gastrointestinal system cancer | no benefit | detail... |
BRAF G466A | Trametinib | gastrointestinal system cancer | no benefit | detail... |
PTEN mutant | Pembrolizumab | gastrointestinal system cancer | decreased response | detail... |
PTEN mutant | Nivolumab | gastrointestinal system cancer | decreased response | detail... |
MSH6 negative | unspecified immune checkpoint inhibitor | gastrointestinal system cancer | predicted - sensitive | detail... |
MLH1 negative | unspecified immune checkpoint inhibitor | gastrointestinal system cancer | predicted - sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01384253 | Phase I | 212Pb-TCMC-Trastuzumab + Trastuzumab | Safety Study of ²¹²Pb-TCMC-Trastuzumab Radio Immunotherapy | Completed | USA | 0 |
NCT01625351 | Phase I | Fludarabine Melphalan Busulfan Alemtuzumab | A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas | Completed | USA | 0 |
NCT01640665 | Phase I | Capecitabine + Sorafenib | Pilot Study of Sorafenib and Bi-weekly Capecitabine in Patients With Advanced Breast and Gastrointestinal Tumors | Completed | USA | 0 |
NCT01916447 | Phase I | Bevacizumab Trifluridine-tipiracil hydrochloride Irinotecan | A Phase I Study of TAS-102 in Patients With Advanced Gastrointestinal Tumors. | Completed | USA | 0 |
NCT02192541 | Phase I | Aflibercept + Ganetespib | Ganetespib and Ziv-Aflibercept in Refractory Gastrointestinal Carcinomas, Non-Squamous Non-Small Cell Lung Carcinomas, Urothelial Carcinomas, and Sarcomas | Terminated | USA | 0 |
NCT02319018 | Phase I | Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Alisertib | Alisertib and Combination Chemotherapy in Treating Patients With Gastrointestinal Tumors | Completed | USA | 0 |
NCT02344810 | Phase Ib/II | AMG 337 Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab | C-Met Inhibitor AMG 337, Oxaliplatin, Leucovorin Calcium, and Fluorouracil in Treating Patients With Advanced Stomach or Esophageal Cancer | Withdrawn | USA | 0 |
NCT02417753 | Phase II | Danvatirsen | AZD9150, a STAT3 Antisense Oligonucleotide, in People With Malignant Ascites | Terminated | USA | 0 |
NCT02757391 | Phase I | Aldesleukin + Cyclophosphamide + Pembrolizumab | T Cell Immunotherapy Plus Anti-PD1 Antibody in Advanced Solid Malignancies | Terminated | USA | 0 |
NCT03412877 | Phase II | Aldesleukin + Cyclophosphamide + Fludarabine + iTCR-transduced PBL Aldesleukin + Cyclophosphamide + Fludarabine + iTCR-transduced PBL + Pembrolizumab | Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated Neoantigens in People With Metastatic Cancer | Recruiting | USA | 0 |
NCT03607643 | Phase Ib/II | Temozolomide Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Bevacizumab + Cannabidiol + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Bortezomib Bortezomib + Cannabidiol Cannabidiol + Gemcitabine Cannabidiol + Temozolomide Gemcitabine | A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies | Unknown status | USA | 0 |
NCT03663712 | Phase I | Talimogene laherparepvec | Talimogene Laherparepvec for the Treatment of Peritoneal Surface Malignancies (TEMPO) | Completed | USA | 0 |
NCT04122625 | Phase Ib/II | Nivolumab + Xevinapant | Study to Assess Safety and Efficacy of the Second Mitochondrial-derived Activator of Caspases (SMAC) Mimetic Debio 1143 (SMARTPLUS-106) | Completed | USA | FRA | ESP | 0 |
NCT04145297 | Phase I | Hydroxychloroquine + Ulixertinib | Ulixertinib (BVD-523) and Hydroxychloroquine in Patients w Advanced MAPK-Mutated Gastrointestinal Adenocarcinomas (UTAH) | Completed | USA | 0 |
NCT04273061 | Phase II | Atezolizumab | Investigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible Sensitivity (CAPTIV-8) | Recruiting | CAN | 0 |
NCT04336241 | Phase I | Nivolumab + RP2 RP2 | Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid Tumors | Recruiting | GBR | ESP | 0 |
NCT04421820 | Phase I | BOLD-100 + Fluorouracil + Leucovorin + Oxaliplatin | BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours | Recruiting | USA | IRL | CAN | 1 |
NCT04535401 | Phase I | Elimusertib + Fluorouracil + Irinotecan + Leucovorin | Testing the Addition of an Anticancer Drug, BAY 1895344, to the Usual Chemotherapy With FOLFIRI in Advanced or Metastatic Cancers of the Stomach and Intestines | Active, not recruiting | USA | 0 |
NCT04591431 | Phase II | Everolimus Nivolumab Itacitinib Erlotinib Ponatinib Pemigatinib Ipatasertib Ipilimumab Cobimetinib Atezolizumab Palbociclib Entrectinib Vemurafenib Lapatinib Trastuzumab Brigatinib Alectinib Ado-trastuzumab emtansine Pertuzumab Vismodegib | The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy (ROME) | Active, not recruiting | ITA | 0 |
NCT05076552 | Phase I | TACH101 | A Study to Assess the Safety, Pharmacokinetics, and Antitumor Activity of Oral TACH101 in Participants With Advanced or Metastatic Cancer | Active, not recruiting | USA | 0 |
NCT05205330 | Phase Ib/II | Balstilimab + CR6086 | CR6086/AGEN2034 Combination in Stage IV pMMR - MSS CRC, and Other Metastatic GI Cancers | Recruiting | ITA | 0 |
NCT05238922 | Phase I | INCB123667 | Study of INCB123667 in Subjects With Advanced Solid Tumors | Recruiting | USA | NLD | ITA | GBR | FRA | CHE | 1 |
NCT06208124 | Phase Ib/II | IMM-6-415 | A Study of IMM-6-415 in RAS/RAF Mutant Solid Tumors | Recruiting | USA | 0 |
NCT06226766 | Phase Ib/II | JSKN033 | JSKN033 in Patients With Advanced or Metastatic Solid Malignant Tumors | Recruiting | AUS | 0 |
NCT06253520 | Phase I | Cyclophosphamide + Fludarabine Aldesleukin + Anti-KRAS G12V TCR cells + GRT-C903 + GRT-R904 Aldesleukin + Anti-KRAS G12D TCR cells + GRT-C903 + GRT-R904 | Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer | Recruiting | USA | 0 |
NCT06389123 | Phase I | 177Lu-DOTA-ABM-5G | Molecularly Targeted Theranostic Approach for the Detection and Treatment of Metastatic Carcinomas | Recruiting | USA | 0 |
NCT06414733 | Phase I | MVF-HER-2(597-626)/MVF-HER-2(266-296) Vaccine | Vaccine Therapy in Treating Patients With Metastatic Solid Tumors | Not yet recruiting | USA | 0 |